Recombinant Herpes Zoster Vaccine (RZV) after Heart Transplantation: A Single Center Experience

Herpes zoster (HZ) results from reactivation of latent varicella zoster virus (VZV) presenting as a dermatomal rash. Diminished cellular immunity to VZV increases HZ risk and incidence in solid organ transplant (SOT) is higher than the general population. Immunogenicity and safety of the inactivated varicella vaccine (RZV, Shingrix) has been demonstrated in renal transplant (KT) but data in heart transplant (HT) are lacking.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: M.H. Barghash, S. Taimur, M. Rana, J. Behar, A. Lala, S.S. Mitter, N. Moss, S.P. Pinney, D. Mancini Tags: (485) Source Type: research